Abstract：Objective To understand the drug resistance rate among HIV-infected people in Xinjiang Uygur Autonomous Region, and to analyze the characteristics of drug resistance sites. Methods Self-developed in-house HIV drug resistance testing method and ViroSeqTM kit were used to detectdrug resistance in 274 HIV-1 patients receiving antiviral therapy and with viral load more than 1,000 copies/ml. The drug resistance status and drug resistance site information of the samples were obtained. The drug resistance rate and mutation characteristics of the samples were further analyzed, and the consistency of results detected by the two methods was compared. Results In-house HIV drug resistance testing displayed that 17 (6.2%) samples showed resistance to protease inhibitors (PIs), 70 (25.5%) samples resistance to nucleoside reverse transcriptase inhibitors (NRTIs), and 119 (43.4%) samples resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs). The main drug-resistant mutations in PIs were I84V and V82A. The most frequent mutation in NRTIs was M184VI (49.2%). The main mutation site in NNRTIs was K103N (51.5%). In addition, the consistency of the two methods to detect PI, NRTI and NNRTI was 94.5%, 98.5% and 92.3%, respectively. Conclusions No specific resistance sites are found in this study. The consistency of results detected by the above-mentioned two methods is high. In-house HIV drug resistance testing method can replace ViroSeqTM kit to expand the coverage of HIV resistance detection.
金涛, 胡晓远, 王凤英, 马媛媛, 倪祯, 倪明健. 新疆274例HIV/AIDS抗病毒治疗耐药分析及两种耐药检测方法比较[J]. 实用预防医学, 2020, 27(12): 1417-1420.
JIN Tao, HU Xiao-yuan, WANG Feng-ying, MA Yuan-yuan, NI Zhen, NI Ming-jian. Drug resistance analysis of antiviral therapy in 274 HIV/AIDS cases in Xinjiang and comparison of two methods for drug resistance detection. , 2020, 27(12): 1417-1420.
[1] Woodyatt CR.World AIDS day 2018[J].Ann Epidemiol,2018,28(12):829 [2] Tang Q, Lu H. HIV/AIDS responses in China should focus on the impact of global integration[J].Biosci Trends,2018,12(5):507-509. [3] Zhang FJ, Pan J, Yu L, et al.Current progress of China's free ART program[J].Cell Res,2005, 15(11-12):877-882. [4] 张福杰.国家免费艾滋病抗病毒药物治疗手册[M].北京:人民卫生出版社,2007:12. [5] Voshavar C. Protease inhibitors for the treatment of HIV/AIDS: recent advances and future challenges[J].Curr Top Med Chem,2019,19(18):1571-1598. [6] Clutter DS, Jordan MR, Bertagnolio S, et al. HIV-1 drug resistance and resistance testing[J].Infect Genet Evol,2016,46:292-307. [7] Kityo C, Thompson J, Nankya I, et al. HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-saharan africa[J].J Acquir Immune Defic Syndr,2017,75(2):e45-e54. [8] Steegen K, Bronze M, Papathanasopoulos MA, et al. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa[J]. J Antimicrob Chemother,2017,72(1):210-219. [9] Chaturbhuj DN, Deshmukh PS, Hingankar NK,et al. Evaluations of an in-house drug resistance method for HIV-1 drug resistance using ViroSeqTM2.0 genotyping system as a gold standard[J]. J Virol Methods,2013,189(1):87-92. [10] Xu S, Li J, Bao Z, et al. Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China[J].Mol Diagn Ther,2010,14(1):31-41. [11] Lu DY, Wu HY, Yarla NS, et al. HAART in HIV/AIDS treatments: future trends[J].Infect Disord Drug Targets,2018,18(1):15-22. [12] 于红缨, 李勇忠, 卫学丰, 等. 怀化市艾滋病患者抗病毒治疗效果及耐药影响因素分析[J].实用预防医学,2020,27(4):455-459. [13] DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: reanalysis of retrospective and prospective studies using a standardized data analysis plan[J].Antivir Ther,2000,5(1):41-48. [14] Teno Res Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study[J].Lancet Infect Dis,2016,16(5):565-575. [15] 佐合拉·吐尔地, 廖玲洁, 董永慧,等. 新疆部分艾滋病病人抗病毒治疗效果和耐药变异分析[J].中国艾滋病性病,2011,17(2):107-110,141. [16] 阿斯亚·艾尼瓦尔, 迪力夏提·亚克甫, 戴江红,等. 新疆伊犁地区2014年HIV感染者抗病毒治疗效果及其影响因素分析[J].中国艾滋病性病,2016,22(2):77-80. [17] 肖培培,卢静,胡海洋,等. 2016年江苏省579例艾滋病抗病毒治疗失败患者HIV-1耐药突变状况及影响因素分析[J].中华预防医学杂志,2017,51(11):988-993. [18] Li XP, Xing H, Wang Z, et al. Study of HIV-1 drug resistance in patients receiving free atiretroviral therapy in China[J].Virologica Sinica,2007,22(3):233-240. [19] Wilke CO. Quasispecies theory in the context of population genetics[J].BMC Evol Biol, 2005,5:44. [20] Onywera H, Maman D, Inzaule S, et al. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naive persons in rural western Kenya[J].PLoS One,2017,12(2):e0171124. [21] Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients[J].J Infect Dis,2004,189(5):837-846. [22] Weng YW, Chen IT, Tsai HC, et al. Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan[J].BMC Infect Dis,2019,19(1):741. [23] Chen X, Zou X, He J, et al. HIV drug resistance mutations (DRMs) detected by deep sequencing in virologic failure subjects on therapy from Hunan province, China[J].PLoS One, 2016,11(2):e0149215.
2020, Vol. 27 
